Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma

Multiple myeloma (MM) pathogenesis remains incompletely understood and biomarkers predicting treatment response still remain lacking. Here we describe the rational mechanisms of combining targeting glautaminase1 (GLS1) with other chemo-reagents for MM treatment. Gls1 is highly expressed cMYC/KRAS12V...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Qiang, Li, Mengyuan, Yang, Linyu, Tang, Minghai, Zheng, Li, Wang, Fang, Qiu, Huandi, Liang, Cailing, Li, Ning, Yi, Dongni, Yi, Yuyao, Pan, Cong, Yang, Shengyong, Chen, Lijuan, Hu, Yiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800263/
https://www.ncbi.nlm.nih.gov/pubmed/31666930
http://dx.doi.org/10.18632/oncotarget.27243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800263/
https://www.ncbi.nlm.nih.gov/pubmed/31666930
http://dx.doi.org/10.18632/oncotarget.27243

Ejemplares similares